WALTHAM, Mass., Dec. 3, 2014 (GLOBE NEWSWIRE) – Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat neuropsychiatric diseases and disorders, today announced the completion of development and final selection of a once-daily dose formulation of MIN-101, an antagonist on 5-HT2A and Sigma2 receptors for the treatment of schizophrenia. The new formulation will be used in the Company’s planned Phase 2b clinical trial in schizophrenia, scheduled to begin recruiting in the first half of 2015.
“The development and final selection of this once-daily formulation of MIN-101 represents an important milestone in our plan to develop a formulation of MIN-101 to achieve optimal efficacy, safety, tolerability and pharmacokinetic profiles,” said Dr. Remy Luthringer, chief executive officer and president of Minerva. “We are especially encouraged by the pharmacokinetic parameters of this formulation and believe it has the ability to address significant areas of unmet need in the treatment of negative symptoms, cognitive impairments and sleep disorders.”